Zolmitriptan inhalation - Acorda Therapeutics

Drug Profile

Zolmitriptan inhalation - Acorda Therapeutics

Alternative Names: CVT 427; Zolmitriptan inhalation powder

Latest Information Update: 05 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Civitas Therapeutics
  • Developer Acorda Therapeutics
  • Class Antimigraines; Oxazolidinones; Small molecules; Tryptamines
  • Mechanism of Action Serotonin 1B receptor agonists; Serotonin 1D receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Migraine

Most Recent Events

  • 27 Apr 2017 Acorda Therapeutics terminates before initiation a phase II trial for Migraine
  • 01 Dec 2016 Acorda Therapeutics completes a phase I trial in Migraine in USA (Inhalation) (NCT02905227)
  • 01 Sep 2016 Acorda Therapeutics initiates a phase I trial for Migraine in USA (Inhalation) (NCT02905227)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top